Liquidia (LQDA) Accumulated Expenses (2019 - 2026)
Liquidia's (LQDA) quarterly Accumulated Expenses came in at $87.7 million in Q1 2026, up 533.83% year-on-year from $13.8 million in Q1 2025, and up 19.85% quarter-over-quarter from $73.2 million in Q4 2025.
Liquidia (LQDA) Accumulated Expenses (2019 - 2026) Analysis & Trends
Liquidia's Accumulated Expenses history runs 8 years deep, the most recent figure standing at $87.7 million for Q1 2026.
- On a quarterly basis, Accumulated Expenses rose 533.83% year-over-year to $87.7 million in Q1 2026; TTM through Mar 2026 was $87.7 million, a 533.83% increase from a year earlier, with the FY2025 full-year figure at $73.2 million, up 614.05% from the prior year.
- Accumulated Expenses rose to $87.7 million in Q1 2026 per LQDA's latest filing, from $73.2 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $87.7 million in Q1 2026 and bottomed at $845000.0 in Q1 2022.
- The 5-year median for Accumulated Expenses is $8.5 million (2023), against an average of $16.5 million.
- Across the five-year window, Accumulated Expenses plunged 43.18% in 2022 and jumped 670.32% in 2023, its largest moves.
- Year by year, Accumulated Expenses stood at $5.5 million in 2022, then jumped by 54.73% to $8.5 million in 2023, then advanced by 19.98% to $10.3 million in 2024, then soared by 614.05% to $73.2 million in 2025, then gained by 19.85% to $87.7 million in 2026.
- Per Business Quant, the three latest LQDA Accumulated Expenses figures stand at $87.7 million (Q1 2026), $73.2 million (Q4 2025), and $8.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.73 Mn |
| Dec 31, 2025 | 73.20 Mn |
| Sep 30, 2025 | 8.74 Mn |
| Jun 30, 2025 | 22.52 Mn |
| Mar 31, 2025 | 13.84 Mn |
| Dec 31, 2024 | 10.25 Mn |
| Sep 30, 2024 | 8.49 Mn |
| Jun 30, 2024 | 13.10 Mn |
| Mar 31, 2024 | 4.72 Mn |
| Dec 31, 2023 | 8.54 Mn |
| Sep 30, 2023 | 3.01 Mn |
| Jun 30, 2023 | 14.77 Mn |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 5.52 Mn |
| Sep 30, 2022 | 2.20 Mn |
| Jun 30, 2022 | 1.92 Mn |
| Mar 31, 2022 | 845,000.00 |
| Dec 31, 2021 | 5.17 Mn |
| Sep 30, 2021 | 2.06 Mn |
| Jun 30, 2021 | 1.62 Mn |